CSIMarket Company Name, Ticker, Suppliers, else..
 
Genprex Inc   (NASDAQ: GNPX)
 
Price: $3.3750 $-0.04 -1.026%
Day's High: $3.5799999237060547 Week Perf: 0.75 %
Day's Low: $ 3.34 30 Day Perf: -14.56 %
Volume (M): 46,606 52 Wk High: $ 55.00
Volume (M$): $ 0 52 Wk Avg: $3.65
Open: $3.50 52 Wk Low: $0.42



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 0
 Employees 13
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -17
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) 0

Business Description


Genprex Inc is a clinical-stage gene therapy company that focuses on developing revolutionary gene-based treatments for cancer. The company aims to deliver its proprietary gene therapies directly to tumors to unleash the body's natural defense mechanisms against cancer. Genprex's lead product candidate, Oncoprex, is being developed to treat multiple types of cancer, including non-small cell lung cancer. The company is dedicated to improving patient outcomes and revolutionizing cancer treatment through innovative gene therapy solutions.


   Company Address: 3300 Bee Cave Road, #650-227 Austin 78746 TX
   Company Phone Number: 537-7997   Stock Exchange / Ticker: NASDAQ GNPX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GERN   -2.92%    
MDGL   -0.82%    
SUPN        2.95% 
TGTX        1.85% 
ZLAB        7.28% 
ZYME        4.65% 
• View Complete Report
   



Stock Offering

Genprex Secures $6.5 Million in Funding to Advance Cancer and Diabetes Therapies

Published Fri, Mar 22 2024 8:10 PM UTC

Genprex Secures $6.5 Million in Funding Through Registered Direct Offering
Genprex, a leading gene therapy company, recently announced the closing of a $6.5 million registered direct offering priced at-the-market under Nasdaq rules. This funding will allow the company to further advance its clinical-stage therapies for patients with cancer and diabetes. With 57.805639 m...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.11
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.47
Working Capital Ratio 6.77
Leverage Ratio (MRQ) 0.16
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -222.8 $
Revenues (TTM) -
Cash Flow (TTM) 35.3 $
Cash 32.03 $
Book Value 31.27 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,269,120
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.